Skip to main content

and
  1. Article

    Open Access

    Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

    The activation of dendritic cells (DCs) is pivotal for generating antigen-specific T-cell responses to eradicate tumor cells. Hence, immunotherapies targeting this interplay are especially intriguing. Moreover...

    Jessica Wenthe, Emma Eriksson, Ann-Charlotte Hellström in Journal of Translational Medicine (2023)

  2. Article

    Open Access

    Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study

    While recent years have seen a revolution in the treatment of metastatic cutaneous melanoma, no treatment has yet been able to demonstrate any prolonged survival in metastatic uveal melanoma. Thus, metastatic ...

    Henrik Jespersen, Roger Olofsson Bagge, Gustav Ullenhag, Ana Carneiro in BMC Cancer (2019)

  3. Article

    Open Access

    Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

    Cancer immunotherapy can be potentiated by conditioning regimens such as cyclophosphamide, which reduces the level of regulatory T cells (tregs). However, myeloid suppressive cells are still remaining. Accordi...

    Emma Eriksson, Jessica Wenthe, Sandra Irenaeus in Journal of Translational Medicine (2016)

  4. Article

    Open Access

    Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

    Current approaches for treating metastatic malignant melanoma (MM) are not effective enough and are associated with serious adverse events. Due to its immunogenicity, melanoma is an attractive target for immun...

    Angelica Loskog, Aglaia Maleka, Sara Mangsbo, Emma Svensson in British Journal of Cancer (2016)